Milena Sant, MD, on The Latest Findings From the EUROCARE 5 Study
2015 European Cancer Congress
Milena Sant, MD, of Istituto Nazionale dei Tumori, discusses the question of whether Europe is doing better in cancer care since the 1990s (Abstract LBA1).
Lisa Carey, MD
Lisa Carey, MD, of the University of North Carolina, discusses heterogeneity, treatment response, and outcome in HER2-positive breast cancer.
Cora N. Sternberg, MD
Cora N. Sternberg, MD, of San Camillo Forlanini Hospital, summarizes a teaching lecture on new targets in renal cell carcinoma, and discusses what to expect for the future of treating RCC.
Federico Cappuzzo, MD, and Tony Mok, MD
Federico Cappuzzo, MD, of Istituto Toscano Tumori-Ospedale Civile Livorno, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss current strategies for treating patients with acquired resistance, and what the future holds for these patients.
Ignacio Melero, MD, PhD
Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses the latest developments in an important cancer treatment avenue.
Jonathan E. Rosenberg, MD
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses this pivotal study of an investigational immunotherapy that has shown increased and durable responses, with a relatively benign toxicity profile (Abstract 21LBA).